No Data
No Data
No Data
No Data
No Data
Market Buzz: Insulet Corporation's (PODD) Stock Soars On Analyst Upgrade
Following an upgraded recommendation by an esteemed analyst firm, the shares of Insulet Corporation (NASDAQ: PODD) exhibited a noteworthy upsurge on the US stock market charts on Tuesday. Wrapping up the trading session, shares of Insulet (PODD) surged by 4.47%, or $7.88, to reach $184.28. On Tuesday, Wolfe Research upgraded its rating for Insulet (PODD) ...
Stocks TelegraphMay 8 18:09
Wolfe Raises Insulet to Outperform, Cites Increasing Market Share
Seeking AlphaMay 7 23:56
Insulet's 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today released its 2023 Sustainability Report, which describes
BusinesswireMay 7 18:00
Insulet Raised to Outperform From Peer Perform by Wolfe Research
Insulet Raised to Outperform From Peer Perform by Wolfe Research
Dow JonesMay 7 17:47
Wolfe Research: Upgraded Insulet (PODD.US) rating from Peer Perform to be superior to market rating, target price $200.00.
Wolfe Research: Upgraded Insulet (PODD.US) rating from Peer Perform to be superior to market rating, target price $200.00.
Zhitong FinanceMay 7 17:40
Insulet Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 13.38% Wolfe Research → $200 Upgrades Peer Perform → Outperform 02/26/2024 20.75% Barclays $214
BenzingaMay 7 17:35
No Data
No Data